BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

Abstract Background Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient’s survival. However, BRAF-muta...

Full description

Bibliographic Details
Main Authors: Evelina Miele, Luana Abballe, Gian Paolo Spinelli, Zein Mersini Besharat, Giuseppina Catanzaro, Martina Chiacchiarini, Alessandra Vacca, Agnese Po, Carlo Capalbo, Elisabetta Ferretti
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Cancer
Subjects:
BRAFV600E mutation
Colon cancer
Molecular therapy
Afatinib
Vemurafenib
ErbB2
Online Access:http://link.springer.com/article/10.1186/s12885-020-6586-0

Internet

http://link.springer.com/article/10.1186/s12885-020-6586-0

Similar Items